Obama's second budget for FDA sets another record

Share this article:
A week after promising non-military government austerity in his State of the Union address, President Obama proposes a second successive record annual hike in FDA funding—up 23% on top of his 19% boost last year—to include new product safety programs and user fees.

The $4.03 billion request includes $601 million in increased user fees and $146 million extra from appropriated congressional funding—a ratio that drew immediate criticism from the Alliance for Stronger FDA, which wants more taxpayer funding of the agency, and less dependency on industry. It said the budget authority request “will sustain FDA's current programming and personnel in FY 2011. It will not enable FDA to add necessary new programs or personnel.”

Obama's proposal would add $100 million for a “Protecting Patients Initiative” to modernize FDA's approach to supply chain safety for medical products and postmarketing surveillance.

Import safety would get $11 million from the budget proposal to launch an electronic drug registration and listing system.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?